{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:32:53Z","timestamp":1789878773437,"version":"4.0.1"},"reference-count":28,"publisher":"European Respiratory Society (ERS)","issue":"1","funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2018,10,28]]},"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:p>Nintedanib and pirfenidone are approved treatments for idiopathic pulmonary fibrosis (IPF). This open-label, two-group trial investigated the pharmacokinetic drug\u2013drug interaction between these two drugs in patients with IPF.<\/jats:p><jats:p>Subjects not treated with antifibrotics at screening (group 1, n=20) received a single nintedanib dose (150\u2005mg) followed by pirfenidone (titrated to 801\u2005mg thrice daily) for 3\u2005weeks, with a further single nintedanib dose (150\u2005mg) on the last day (day 23). Subjects treated with pirfenidone at screening (group 2, n=17) continued to receive pirfenidone alone (801\u2005mg thrice daily) for 7\u2005days, then co-administered with nintedanib (150\u2005mg twice daily) for a further 7\u2005days, before single doses of both treatments on day 16.<\/jats:p><jats:p>In group 1, adjusted geometric mean (gMean) ratios (with\/without pirfenidone) were 88.6% and 80.6% for nintedanib area under the plasma concentration\u2013time curve (AUC) and maximum plasma concentration (C<jats:sub>max<\/jats:sub>), respectively. In group 2, gMean ratios (with\/without nintedanib) were 97.2% and 99.5% for pirfenidone AUC and C<jats:sub>max<\/jats:sub>, respectively. For all parameters, the 90% confidence intervals included 100%, suggesting similar exposure for administration alone and when co-administered. Both treatments were well tolerated.<\/jats:p><jats:p>These data indicate there is no relevant pharmacokinetic drug\u2013drug interaction between nintedanib and pirfenidone when co-administered in IPF patients.<\/jats:p>","DOI":"10.1183\/13993003.01060-2018","type":"journal-article","created":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T10:59:17Z","timestamp":1542279557000},"page":"1801060","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":28,"title":["No relevant pharmacokinetic drug\u2013drug interaction between nintedanib and pirfenidone"],"prefix":"10.1183","volume":"53","author":[{"given":"Luca","family":"Richeldi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huzaifa","family":"Adamali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazia","family":"Chaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Wiebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Wind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Hohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozsa","family":"Schlenker-Herceg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Stowasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby M.","family":"Maher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2018,11,15]]},"reference":[{"key":"2024102100423249000_53.1.1801060.1","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102100423249000_53.1.1801060.2","doi-asserted-by":"crossref","first-page":"17074","DOI":"10.1038\/nrdp.2017.74","article-title":"Idiopathic pulmonary fibrosis","volume":"3","author":"Martinez","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"2024102100423249000_53.1.1801060.3","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01209-2017"},{"key":"2024102100423249000_53.1.1801060.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60405-4"},{"key":"2024102100423249000_53.1.1801060.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402584"},{"key":"2024102100423249000_53.1.1801060.6","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201506-1063ST"},{"key":"2024102100423249000_53.1.1801060.7","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1164\/rccm.201709-1939ED","article-title":"Combination therapy and the start of a new epoch for idiopathic pulmonary fibrosis?","volume":"197","author":"Maher","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102100423249000_53.1.1801060.8","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S2213-2600(14)70232-2","article-title":"Combination therapy: the future of management for idiopathic pulmonary fibrosis?","volume":"2","author":"Wuyts","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2024102100423249000_53.1.1801060.9","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1164\/rccm.201706-1301OC","article-title":"Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis. Results of the INJOURNEY trial","volume":"197","author":"Vancheri","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102100423249000_53.1.1801060.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30866-8"},{"key":"2024102100423249000_53.1.1801060.11","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1080\/13543784.2017.1364361","article-title":"Investigational drugs for idiopathic pulmonary fibrosis","volume":"26","author":"Varone","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"2024102100423249000_53.1.1801060.12","unstructured":"European Medicines Agency. Esbriet (Pirfenidone): Summary of Product Characteristics. www.ema.europa.eu\/documents\/product-information\/esbriet-epar-product-information_en.pdf \u00a0Date last accessed: November 30 2017. Date last updated: October 31 2017."},{"key":"2024102100423249000_53.1.1801060.13","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201600892RR"},{"key":"2024102100423249000_53.1.1801060.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2014.02.014"},{"key":"2024102100423249000_53.1.1801060.15","unstructured":"European Medicines Agency. Ofev (Nintedanib): Summary of Product Characteristics . https:\/\/www.ema.europa.eu\/documents\/product-information\/ofev-epar-product-information_en.pdf Date last accessed: November 30 2017. Date last updated: September 19 2017."},{"key":"2024102100423249000_53.1.1801060.16","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00174914"},{"key":"2024102100423249000_53.1.1801060.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402582"},{"key":"2024102100423249000_53.1.1801060.18","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00198013"},{"key":"2024102100423249000_53.1.1801060.19","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) Assessment Report for Esbriet (Pirfenidone) . www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002154\/WC500103073.pdf Date last accessed: November 30 2017. Date last updated: December 16 2010."},{"key":"2024102100423249000_53.1.1801060.20","doi-asserted-by":"publisher","DOI":"10.3109\/00498254.2010.545452"},{"key":"2024102100423249000_53.1.1801060.21","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) Assessment Report for Ofev (nintedanib) . www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/003821\/WC500182476.pdf Date last accessed: November 30 2017. Date last updated: November 20 2014."},{"key":"2024102100423249000_53.1.1801060.22","unstructured":"European Medicines Agency. Committee for Human Medicinal Products (CHMP). Guideline on the Investigation of Bioequivalence . CPMP\/EWP\/QWP\/1401\/98 Rev. 1. www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2010\/01\/WC500070039.pdf Date last accessed: November 30 2017. Date last updated: January 20, 2010."},{"key":"2024102100423249000_53.1.1801060.23","unstructured":"Chow S , Liu J . Design and Analysis of Bioavailability and Bioequivalence Studies. New York, Marcel Dekker, 1992."},{"key":"2024102100423249000_53.1.1801060.24","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-013-9962-7"},{"key":"2024102100423249000_53.1.1801060.25","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/jcph.752","article-title":"Pharmacokinetic properties of nintedanib in healthy volunteers and patients with advanced cancer","volume":"56","author":"Dallinger","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"2024102100423249000_53.1.1801060.26","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00011514"},{"key":"2024102100423249000_53.1.1801060.27","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1159\/000485933","article-title":"Real-world experience with nintedanib in patients with idiopathic pulmonary fibrosis","volume":"95","author":"Brunnemer","year":"2018","journal-title":"Respiration"},{"key":"2024102100423249000_53.1.1801060.28","first-page":"PA2089","article-title":"Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF","volume":"48","author":"Taniguchi","year":"2016","journal-title":"Eur Respir J"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.01060-2018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T07:00:47Z","timestamp":1740380447000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.01060-2018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,15]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,1,10]]},"published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1183\/13993003.01060-2018"],"URL":"https:\/\/doi.org\/10.1183\/13993003.01060-2018","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,15]]}}}